Tien Hoang

Researcher Profile 6/10

Dalat University · Medicine and Pharmacy

96 publications · 3,727 citations · h-index 26

Information

🏛️Affiliation: Dalat University
🔬Field: Medicine and Pharmacy
🆔ORCID: 0009-0002-4154-578X
✍️Profile incomplete — add information

An h-index of 26 places this researcher in Medicine and Pharmacy, within the top 5% of 6,619 profiles in this field in our directory.

Featured publications

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial615 citations
Journal of Thoracic Oncology · 2020 · DOI

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial467 citations
Journal of Thoracic Oncology · 2020 · DOI

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial347 citations
The Lancet Oncology · 2017 · DOI

Clinical Model to Predict Survival in Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer Treated With Third-Generation Chemotherapy Regimens Based on Eastern Cooperative Oncology Group Data265 citations
Journal of Clinical Oncology · 2004 · DOI

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.220 citations
Journal of Clinical Oncology · 2018 · DOI

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck147 citations
Annals of Oncology · 2012 · DOI

Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.144 citations
Journal of Clinical Oncology · 2015 · DOI

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer121 citations
Journal of Clinical Oncology · 2023 · DOI

OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC120 citations
Journal of Thoracic Oncology · 2018 · DOI

Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer89 citations
Lung Cancer · 2008 · DOI

About the field of Medicine and Pharmacy

6,619researchers 91,896publications 2,589,484citations 4.2average h-index

Common research topics in this field:

Mosquito-borne diseases and controlAntibiotic Resistance in BacteriaTuberculosis Research and EpidemiologyMalaria Research and ControlCOVID-19 and Mental HealthHIV/AIDS Research and Interventions

Institutions with the most researchers in this field: